Drogasil streak mira expansion into other niches

(Subject changed to correct information. Philipe, and not Ab is Active investment Economist, and not analyst. Follow the full corrected) before a more competitive market and sprayed, the streak Drogasil redesigns gradually your business strategy beyond the traditional focus on large urban centers and social classes A and b. To 2019, the pharmaceutical network must broaden the mix of generic products and accelerate actions of digital transformation. " In 2018, we face a challenging competitive environment. However, we have achieved significant gains in terms of revenue market share by investing in generics. This category has reached another level in our product mix, which allows us to compete harder in the future, "explained the President of the pharmaceutical network via teleconference to the market, Marcilio Pousada.De accordance with the Executive, one of the focuses of the business for the year will be "leveraging the popular driver" keeping the pace of opening shops in the North and Northeast Regions, expanding the self-service nature of operations and investing in initiatives for the omnichannel. "We realize that customers who traditionally buy the internet showing greater maturity and are more faithful to the business. Thus, we see the cell phone as a base to build a solid relationship with the consumer, "said Posada, noting also that this movement will involve investing in a process of more accurate data analysis. Disclosure of quarterly results, the pharmaceutical network announced the acquisition of another player in the market, Onofre. For hostel, the acquisition-which did not have their values disclosed and still need to be approved by the Administrative Council for economic Defense (Cade)-was regarded as a chance to accelerate the digital transformation of the company. According to him, about 45% of the gross revenue of Olango is coming from e-commerce. " The units are in good commercial points Onofre. See in this sense a business opportunity to join the buying Streak scale Drogasil and unify of distribution centers, "said the Executive. In the same perspective of reasoning, the Active investment Economist Philipe Ab, says that the strategic positioning of the pharmaceutical network is a direct result of the fierce competition in the market. "The retail pharmaceutical sector is one of the most competitive, and sprayed it has been intensifying in recent years. In the case of Lane Drogasil, the acquisition of Onofre came as an opportunity to expand the segment using the strong e-commerce development in other regions, "argued Aguiar. Still according to him, the benefits to the acquisition will be observed at both ends: the consumer will have more convenience and will face less friction in time to perform an online purchase and operating costs of Drogasil Streak should decrease. "In addition, the initiative should also impact the competition with the networks that have regional activities in the North and northeast of the country," added he. Balance in the report on performance during the year 2018, Drogasil Streak 7% increment released in net profits compared to the previous year – reaching R $548.6 million. With regard to market share gain, there was 0.9 percentage point advance (p.p.) in the period, resulting in a total participation of 12.9%. "One of our achievements was the record market share gain," commented the President of the network. According to him, the company must keep the pace of opening of shops registered last year, with 240 new operations in 2019. In addition, the goal of the network is to reach 2 million active customers on multicanalidade by the end of the year – at the end of 2018, that quota was around 400,000 consumers. Already in relation to Ebitda (earnings before interest, taxes, depreciation and amortization) of the retailer, there was an increase of 5.7% in the period – coming to R $1.1 billion. As featured negative cash flow of the company, which presented negative balance around £ $139 million last year.